AVR 0.00% $12.00 anteris technologies ltd

Ann: HSV-2 Phase IIa Results Investor Webinar, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,142 Posts.
    lightbulb Created with Sketch. 1
    ASX ANNOUNCEMENT Brisbane, 1st May, 2017 ADMEDUS HSV-2 PHASE IIa RESULTS WEBINAR • Admedus investor webinar Thursday, 4 May 2017 • 9am AEST Sydney/Melbourne/Brisbane time; 7am AWST Perth time Admedus Limited (ASX:AHZ) today announced that it will hold an investor webinar on Thursday, 4 May 2017 to present the results of the HSV-2 Phase IIa program and provide a business overview on the rest of its immunotherapies programs including the HPV treatment program and its work in the area of RNA vaccines. The webinar details Date: 4 May, 2017 Time: 9am Australian Eastern Standard Time (AEST); 7am Australian Western Standard Time (ASWT) Please register to attend the webinar at: https://attendee.gotowebinar.com/register/2780413500734718467 Follow us: Twitter: @Admedus Facebook: www.facebook.com/pages/Admedus Website: www.admedus.com
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.